Cutaneous leishmaniasis;Leishmaniasis cutánea

Actas Dermo-Sifiliograficas

Volumn 96, Issue 1, 2005, Pages 1-24

  García Almagro, Domingo ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

Leishmania infantum; Leishmaniasis; Oriental boil

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; ANTIMONY; C REACTIVE PROTEIN; CARBON; CHALCONE DERIVATIVE; CLOTRIMAZOLE; FLAVONOID; GAMMA INTERFERON; GENTAMICIN; IMIQUIMOD; INTERLEUKIN 12; INTERLEUKIN 2; ITRACONAZOLE; KANAMYCIN; KETOCONAZOLE; LACTATE DEHYDROGENASE; LIQUID NITROGEN; MEGLUMINE ANTIMONATE; MICONAZOLE; MILTEFOSINE; NITROUS OXIDE; PAROMOMYCIN; PENTAMIDINE; PYRAZOLOPYRIMIDINE DERIVATIVE; RIFAMPICIN; SITAMAQUINE; STIBOGLUCONATE SODIUM; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ABDOMINAL PAIN; ANTIGEN ANTIBODY REACTION; ARTHRALGIA; BIOPSY; CLINICAL FEATURE; CRYOTHERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG HYPERSENSITIVITY; ELECTRON MICROSCOPY; ELECTROSTIMULATION THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; GENOTYPE; HISTOPATHOLOGY; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHERMIC THERAPY; IMMUNOFLUORESCENCE; LEISHMANIA INFANTUM; MYALGIA; NATURAL KILLER CELL; NAUSEA AND VOMITING; PANCREATITIS; PARASITE CULTIVATION; PARASITE IDENTIFICATION; PARASITE VECTOR; PERIPHERAL NEUROPATHY; PHENOTYPE; PHLEBOTOMUS; POLYMERASE CHAIN REACTION; PREVALENCE; PSYCHODIDAE; RANDOM AMPLIFIED POLYMORPHIC DNA; RASH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SKIN LEISHMANIASIS; SPAIN; TAXONOMY;

EID: 15944425421     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-7310(05)73027-1     Document Type: Review

References (182)

1. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases. WHO/CDS/CSR/ISR/2000.1.
2. Alvar J. Las leishmaniasis en España. En: Alvar J, editor. Las leishmaniasis: de la biología al control. 2.a ed. Salamanca: Laboratories Intervet, 2001; p. 95.
3. Albero Blancs F, Martínez Sánchez C, Román Maciá P. Leishmaniasis cutánea. Alcoy: zona endémica. Actas Dermo-Sif 1979;70:475-84.
4. Coscojuela C, Martín J, Grasa P, et al. Leishmaniasis cutánea en Aragón (España). Actas Dermo-Sif 1987;78(Supl I): 93-122.
5. Alcalde Alonso M, Morillas Márquez F, Delgado Florencio V, et al. Epidemiología de las leishmaniosis cutáneas en la provincia de Granada. Actas Dermo-Sif 1989;80: 251-4.
6. Daudén E, García C, Zarco C, et al. Leishmaniasis cutánea en el foco endémico de Madrid. Estudio de 31 casos. Actas Dermo-Sif 1990;81:395-404.
7. Sesma B, Barricarte A. Leishmaniasis en Navarra: Revisión de actuaciones. Anales del Sistema Sanitario de Navarra 1997. URL disponible en: www.cfnavarra.es/salud/anales/textos/vol20/n2/salud3a.html.
8. Urrutia S, García C, Schoendorff C, et al. Leishmaniasis cutánea en la provincia de Toledo. Estudio de 43 pacientes. Actas Dermosifiliogr 2000;91:1-8.
9. Oumeish YO. Cutaneous Leishmaniasis: A historical perspective. Clin Dermatol 1999;17:257-60.
10. Allison MJ. Leishmaniasis. En: Kiple KF, editor. The Cambridge History of Human Disease. Cambridge: Cambridge University Press, 1993.
11. Botet J, Portus M. La leishmaniasis en la España peninsular. Revisión histórico bibliográfica (1912-1985). Rev San Hig Publ 1993;67:255-66.
12. Vilanova X. Utilidad de los tratamientos de orden general en determinadas formas de leishmaniosis cutánea mediterránea. Actas Dermo-Sif 1942;33:526-7.
13. Vilanova J. Fundamentos, técnica y resultados obtenidos en el tratamiento intralesional del botón de Oriente con un nuevo preparado de antimonio a alta concentración. Rev Clin Esp 1943;8:21-8.
14. Gunders AE, Lidror R, Montillo B, et al. Isolation of Leishmania sp. from Psammomys obesus in Judea. Trans R Soc Trop Med Hyg 1968;62:465.
15. De la Loma A, Alvar J, Martínez E, et al. Leishmaniasis or AIDS? Trans R Soc Trop Med Hyg 1985;79:421-2.
16. Alvar J, Gutiérrez-Solar B, Pachón I, et al. AIDS and Leishmania infantum. New approaches for a new epidemiological problem. Clin Dermatol 1996;14:541-6.
17. Chang PCH. The ultrastructure of Leishmania donovani. J Parasitol 1956;42:126-36.
18. González González G, Rodríguez González C, Simón Merchán A. Morfología de la Leishmania tropica en su estado intracelular en la dermis humana. Actas Dermo-Sif 1976;67:527-34.
19. Dedet JP, Pratlon F, Lanotte G, et al. The parasite. Clin Dermatol 1999;17:261-8.
20. Kaysel Cruz A, Orsini Tosi LR. Molecular biology. Clin Dermatol 1996;14:533-40.
21. Sacks DL, Perkins PV. Development of infective stage Leishmania promastigotes within Phlebotomine sandflies. Am J Trop Med Hyg 1985;34:456-9.
22. Kamhawi S, Modi GB, Pimenta PF, et al. The vectorial competence of Phlebotomus sergenti is specific for Leishmania tropica and isw controlled by species-specific, lipophosphoglycan-mediated midgut attachement. Parasitology 2000;121:23-53.
23. Weigle K, Saravia NG. Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous leishmaniasis. Clin Dermatol 1996;14:433-50.
24. Lainson R, Shaw JJ. The Role of animals in the epidemiology of South American leishmaniasis. En: Lumsden WHR, Evans DA, editors. Biology of the Kinetoplastida. London: Academic Press, 1979; p. 1-116.
25. Gardener PJ, Chance ML, Peters W. Biochemical taxonomy of Leishmania. II. Electrophoretic variation of malate dehydrogenase. Ann Trop Med Parasit 1974;68: 317-25.
26. Godfrey DG. The zymodemes of trypanosomes. En: Problems in the identification of the parasites and their vectors. Proceedings of the Symposium of the British Society of Parasitology 1979;17:31-53.
27. McMahon Pratt D, David JR. Monoclonal antibodies that distinguish between New World species of Leishmania. Nature 1981;291:581-3.
28. McMahon Pratt D, Jaffé CL, Bennett E, et al. Studies employing monoclonal antibodies for the analysis of the genus Leishmania Ross, 1903. En: Rioux JA, editor. Leishmania. Taxonomie et phylogenése. Montpellier: IMEEE/CNRS/INSERM, 1986; p. 173-8.
29. Berberian DA. Succesful transmission of cutaneous leishmaniasis by the bite of Stomoxys calcitrans. Proc Soc Exp Biol Med 1938;38:254-6.
30. Killick-Kendrick R. The Biology and control of Phlebotomine Sand Flies. Clin Dermatol 1999;17:279-89.
31. Lane RP. Sandflies (Phlebotominae). En: Lane RP, Crosskey RW, editors. Medical insects and arachnids. London: Chapman and Hall, 1993; p. 78-119.
32. Urrutia S, García Almagro D, González Herrada C, et al. Leishmaniasis cutánea en la provincia de Toledo. XVIII Congr Nac Acad Esp Dermatol. Sevilla, 1989; p. 95.
33. Killick-Kendrick R, Wilkes TJ, Bailly M, et al. Preliminary field observations on the flight speed of a phlebotomine sandfly. Trans R Soc Trop Med Hyg 1986;80:138-42.
34. Schlein Y, Warburg A. Phytophagy and the feeding cycle of Phlebotomus papatassi (Diptera: Psychodidae) under experimental conditions. J Med Ent 1986;23:11-5.
35. World Health Organization. Control of the Leishmaniasis, tecnical report series 397. Genève: World Health Organization, 1990.
36. Saliba EK. Reservoir hosts of cutaneous leishmaniasis. Clin Dermatol 1999;17:275-7.
37. Ashford RW. Leishmaniasis reservoirs and their significance in control. Clin Dermatol 1996;14:523-32.
38. Alvar J, Nieto J. Leishmaniasis canina. En: Alvar J, editor. Las leishmaniasis: de la biología al control. 2.a ed. Salamanca: Laboratories Intervet, 2001; p. 95.
39. Beach R, Kiilu G, Leeuwenburg J. Modification of sand fly bitting behaviour by Leishmania leads to increase parasite transmission. Am J Trop Med Hyg 1985;34:278-82.
40. Schlein Y, Jacobsen RL, Messer G. Leishmania infections damage the feeding mechanism of the sandfly vector and implement parasite transmission by bite. Proc Natl Acad Sci USA 1992;89:9944-8.
41. Kamhawi S. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections. Microbes Infect 2000;2:1765-73.
42. Ribeiro JMC, Vachereau A, Modi GB, et al. A novel vasodilatory peptide from the salivary glands of the sand fly Lutzomya longipalpis. Science 1989;243:212-4.
43. Ribeiro JMC, Katz O, Pannell LK, et al. Salivary glands of the sand fly Phlebotomus papatau contain pharmacologically active amounts of adenosine and 5′ AMP. J Exp Biol 1999;202:1551-9.
44. Chang K-P, Akman L, Nielsen JS. Leishmania virulence and genetic heterogeinity. Clin Dermatol 1999;17:269-73.
45. Turco SJ, Descoteaux A. The lipophosphoglycan of Leishmania parasites. Ann Rev Microbiol 1992;46:65-94.
46. Liew FY. The role of nitric oxide in parasitic disease. Am Trop Med Parasitol 1993;87:637-42.
47. Marletta MA. Nitric oxide synthetase: Aspects concerning structure and catalysis. Cell 1994;78:927-30.
48. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001;166: 1141-7.
49. Burns JM, Shereffler WG, Benson DR, et al. Molecular characterizacion of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci USA 1993;90:775-9.
50. Liew FY, O'Donnell CA. Immunology of Leishmaniasis. Adv Parasitol 1993;32:161-81.
51. Lara ML, Larysse A, Scorza JV, et al. Immunogenetics of human American cutaneous leishmaniasis. Study of HLA haplotypes in 24 families from Venezuela. Hum Inmunol 1991;30:129-35.
52. Petzl-Erler ML, Belich MP, Queiroz-Téllez F. Association of mucosal leishmaniasis with HLA. Hum Inmunol 1991;32: 254-60.
53. Mosmann TR, Cherwinsky H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Inmunol 1986;136:2348-57.
54. Scott P. The role of Th1 and Th2 cells in experimental cutaneous leishmaniasis. Exp Parasitol 1989;68:369-72.
55. McSorley S, Proudfoot L, O'Donnell CA, et al. Immunology of murine leishmaniasis. Clin Dermatol 1996;14: 451-64.
56. Ghersetich I, Menchini G, Teofoli P, et al. Immune response to Leishmania infection in human skin. Clin Dermatol 1999;17:333-8.
57. Babaloo Z, Kaye PM, Eslami MB. Interleukin-13 in Iranian patientes with visceral leishmaniasis: relationship to other Th2 and Th1 cytoquines. Trans R Soc Trop Med Hyg 2001; 95:85-8.
58. Bourreau E, Prevot G, Pradinaud R, et al. Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12. J Infect Dis 2001;183:953-9.
59. Scott CL, Roe L, Curtis J, et al. Mice unresponsive to GM-CSF are unexpectedly resistant to cutaneous Leishmania major infection. Microbes Infect 2000;2:1131-8.
60. Bisti S, Konidou G, Papageorgiou F, et al. The outcome of Leishmania major experimental infection in BALB/c mice can be modulated by exogenously delivered iron. Eur J Inmunol 2000;30:3732-40.
61. Satoskar AR, Bozza M, Rodriguez Sosa M, et al. Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect Immun 2001;69:906-11.
62. Schilling S, Glaichenhaus N. T cells that react to the immunodominant Leishmania major LACK antigen prevent early dissemination of the parasite in susceptible BALB/c mice. Infect Immun 2001;69:1212-4.
63. Nashed BF, Maekawa Y, Takashima M, et al. Different cytokines are required for induction and maintenance of the Th2 type response in DBA/2 mice resistant to infection with Leishmania major. Microbes Infect 2000;2: 1435-43.
64. Vivira LQ, Hondowicz B, Alfonso LC, et al. Infection with Leishmania major induces interleukin 12 production in vivo. Immunol Lett 1994;40:157-61.
65. Smith LE, Rodrigues M, Russell DG. The interaction between CD8+ cytotoxic T cells and Leishmania-infected macrophages. J Exp Med 1991;174:499-505.
66. Stefani MMA, Muller I, Louis JA. Leishmania major specific CD8+ T cells are inducers and targets of nitric oxide produced by parasitized macrofages. Eur J Immunol 1994;24: 746-52.
67. Ferrick DA, Schrenzel MD, Mulvania T, et al. Differential production of interferon-gamma and interleukin-4 in response to % Th-1 and Th-2 stimulating patogens by gamma-delta T cells in vivo. Nature 1995;373:255-7.
68. Schonlau F, Schaffetter-Kochanek K, Grabbe S, et al. In experimental leishmaniasis deeficiency of CD18 results in parasite dissemination associated with altered macrophage functions and incomplete Th1 cell response. Eur J Immunol 2000;30:2729-40.
69. Jaffé CL. Recent trends in vaccine development and immunization. Clin Dermatol 1999;17:339-44.
70. Convit J. Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela. Clin Dermatol 1996;14: 479-87.
71. Milon G, Belkaid Y, Moufqia J, et al. Mononuclear phagocytes and dendritic leukocytes in the skin. Clin Dermatol 1996;14:465-70.
72. Blank C, Fuchs H, Raspersberg K, et al. Parasitism of epidermal Langerhans cells in experimental cutaneous leishmaniasis with Leishmania major. J Infect Dis 1993;167: 418-25.
73. Moll H, Fuchs H, Blank C, et al. Langerhans cells transport Leishmania major from the iunfected skin to the draining lymph node for presentation to antigen-specific T cells. Eur J Inmunol 1993;23:1595-601.
74. Berger T, Meltzer M, Oster CN. Lymph node involvement in leishmaniasis. J Am Acad Dermatol 1985;12:993-6.
75. Travi BL, Rey-Ladino J, Saravia NG. Behaviour of Leishmania braziliensis in golden hamsters: Evolution of the infection under different experimental conditions. J Parasit 1988;74:1059-62.
76. Barker JWN, Mitra RS, Griffiths CEM, et al. Keratinocytes as initiators of the inflammation. Lancet 1991;337:211-4.
77. Mirckovich GF, Galelli A, Allison AC, et al. Increased myelopoiesis during L. major infection on mice: Generation of «safe target», a possible way to evade the efector immune mechanism. Clin Exp Inmunol 1986;64:1-6.
78. Salman SM, Rubeiz NG, Kibbi A-G. Cutaneous leishmaniasis: Clinical features and diagnosis. Clin Dermatol 1999;17:291-6.
79. Kubba R, Al-Gindan Y, El-Hassan AM, et al. Clinical diagnosis of cutaneous leishmaniasis. J Am Acad Dermatol 1987;16:1183-9.
80. Kubba R, El Hassan AM, Al Gindan Y, et al. Dissemination in cutaneous leishmaniasis. I Subcutaneous nodules. Int J Dermatol 1987;26:300-4.
81. Kubba R, Al-Gindan Y, El-Hassan AM, et al. Dissemination in cutaneous leishmaniasis. II Satellite papules and subcutaneous induration. Int J Dermatol 1988;27:702-6.
82. Al Qurashi AR, Ghandour AM, Osman M, et al. Dissemination in cutaneous leishmaniasis due to Leishmania major in different ethnic groups in Saudi Arabia. Int J Dermatol 2000;39:832-6.
83. Dowlati Y. Cutaneous leishmaniasis: Clinical aspect. Clin Dermatol 1996;14:425-31.
84. Marsal Feliudábalo J, Roca de Viñals R. Un caso de leishmaniosis cutánea múltiple con localización en una extremidad. Actas Dermo-Sif 1943;34:471-3.
85. Gómez Orbaneja J, Ledo A. Un caso de leishmaniosis, botón de Oriente, de tipo nodular. Actas Dermo-Sif 1955;46: 815-6.
86. Gómez Orbaneja J, Sancho. Evolución de un caso de leishmaniosis, botón de Oriente, de tipo nodular múltiple, bajo la acción de varias terapéuticas. Actas Dermo-Sif 1957;48:433.
87. Grasa Jordán MP, Marrón Gasca J, Lázaro Pérez J, et al. Leishmaniosis en placas. Actas Dermo-Sif 1978;69:107-14.
88. Haim S. tropica presenting as macrocheilia. Dermatologica 1975;150:292-4.
89. Torres V, Castells A, Martínez Signes V, et al. Leishmaniosis simulando un L.E. Actas Dermo-Sif 1983;74:464.
90. Daudén E, Peñas PE, Ríos L, et al. Leishmaniasis presenting as a dermatomyositis-like eruption in AIDS. J Am Acad Dermatol 1996;35:316-9.
91. Noguer-Moré S. Leishmaniosis cutaneomucosa de la nariz simulando el lupus eritematoide. Actas Dermo-Sif 1944; 35:374-80.
92. Vilanova X. Leishmaniosis de ambos lóbulos de las orejas, a tipo lupoide clínico e histológico con numerosas formaciones pseudocomedonianas en superficie Actas Dermo-Sif 1942;33:621-5.
93. Noguer-Moré S, Noguer Debray S, Roca de Vinyals R. Leishmaniosis cutánea tuberculoide. Leishmaniosis a tipo sarcoide. Actas Dermo-Sif 1960;51:271-8.
94. Miró Carbonell. Leishmaniosis cutánea. Actas Dermo-Sif 1941;32:661-3.
95. Mercadal Peyrí J, Dulanto F. Las formas epiteliomatoides de la leishmaniosis cutánea. Actas Dermo-Sif 1942;33: 616-20.
96. Mercadal Peyrí J. Las formaciones gigantes de la leishmaniosis cutánea. Actas Dermo-Sif 1944;36:56-60.
97. Álvarez Lovell, Puchol, Morán. Contribución al estudio de las leishmaniosis. Actas Dermo-Sif 1945;37:178-90.
98. Sainz de Aja E. Leishmaniasis cutaneomucosa. Actas Dermo-Sif 1929;22:57-9.
99. Srebrink A, Brenner S. Leishmaniasis recidivans mimicking lupus vulgaris. Int J Dermatol 1996;35:572-3.
100. Saravia NG, Weigle K, Segura I, et al. Recurrent lesions in human Leishmania braziliensis infection: Reactivation or reinfection? Lancet 1990;336:398-402.
101. Soler Burgos J. Leishmaniosis «sine leishmania». Actas Dermo-Sif 1946;37:579-82.
102. Grevelink SA, Lerner EA. Leishmaniasis. J Am Acad Dermatol 1996;34:257-72.
103. Convit J, Ulrich M, Fernández CT, et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1993;87:444-8.
104. Zijlstra EE, Khalil EAG, Kager PA, et al. Post-kala-azar dermal leishmaniasis in the sudan: clinical presentation and differential diagnosis. Br J Dermatol 2000;143:136-43.
105. WHO. The leishmaniases and Leishmania/HW co-infections. WHO/QMS fact sheet N.01, Revisada 20-may-2000. URL disponible en: http://www.who.int
106. Desjeux P. Global control and Leishmania HIV co-infeccion. Clin Dermatol 1999;17:317-25.
107. Alvar J. Leishmaniasis and AIDS co-infection: the Spanish example. Parasitol Today 1994;87:160-3.
108. Molina I, Ramón D, Jordá E, et al. Leishmaniasis con diseminación cutánea en el curso de un Síndrome de Inmunodeficiencia Adquirida. Actas Dermo-Sif 1990;81:669-71.
109. De Pablo P, Ivars J, Ortiz FJ, et al. Leishmaniasis cutánea atípica y porfiria hepatocutánea tarda en un paciente con infección por el virus de la inmunodeficiencia humana. Actas Dermo-Sif 1991;82:643-7.
110. Rubio FA, Robayna G, Herranz P, et al. Leishmaniasis presenting as a psoriasiform eruption in AIDS. Br J Dermatol 1997;136:792-806.
111. González-Beato MJ, Moyano B, González-Beato MT, et al. Kaposi's sarcoma-like lesions and other nodules as cutaneous involvemente in AIDS-related visceral leishmaniasis. Br J Dermatol 2000;143:1316-8.
112. Al-Jitawi SA, Farraj SE, Ramahi SA. Conventional scraping versus fine needle aspiration cytology in the diagnosis of cutaneous leishmaniasis. Acta Cytol 1995;39:82-4.
113. Kassi M, Tarren I, Qazi A, et al. Fine-needle aspiration cytology in the diagnosis of cutaneous leishmaniasis. Ann Saudi Med 2004;24:93-7.
114. Reed SG. Diagnosis of Leishmaniasis. Clin Dermatol 1996; 14:471-8.
115. Mehregan DR, Mehregan AH, Mehregan DA. Histologic diagnosis of cutaneous leishmaniasis. Clin Dermatol 1999; 17:297-304.
116. Kurban AK, Malak JA, Farah FS, et al. Histopathology of cutaneous leishmaniasis. Arch Dermatol 1966;93:396-401.
117. Kerdel-Vegas F. American leishmaniasis. Int Soc Trop Dermatol 1982;21:291-303.
118. El-Shoura SM, Tallab T, Bahamdan K. Human cutaneous leishmaniasis. Ultraestructural interactions between the inflamatory cells and Leishman bodies in the skin lesions. Parasite 1996;3:229-36.
119. Momeni AZ, Yotsumoto S, Mehregan DR, et al. Chronic lupoid leishmaniasis. Arch Dermatol 1996;132:198-202.
120. Farah FS, Malak JA. Cutaneous leishmaniasis. Arch Dermatol 1971;103:467-74.
121. Samady JA, Janniger CK, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis. Pediatric Dermatol 1996;57: 13-20.
122. Perrin C, Taillan B, Hofman P, et al. Atypical cutaneous histological features of visceral leishmaniasis in Acquired Immunodeficiency Syndrome. Am J Dermatopah 1995;17: 145-50.
123. Gallego MA, Aguilar A, Plaza S, et al. Kaposi's Sarcoma with an intense parasitization by Leishmania. J Am Acad Dermatol 1996;57:103-5.
124. Barrio J, Lecona M, Cosín J, et al. Leishmania infection occurring in herpes zoster lesions in an HIV-positive patient. Br J Dermatol 1996;134:164-6.
125. Pirmez C, Yamamua M, Uyemura K, et al. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993;91:1390-5.
126. Modlin RL, Pirmez C, Hofman FM, et al. Lymphocites bearing antigen-specific T-cell receptors accumulate in human infectious disease lesions. Nature 1989;339:544-8.
127. Kenner JR, Aronson NE, Bratthauer GL, et al. Immunohistochemistry to identify Leishmania parasites in fixed tissues. J Cutan Pathol 1999;26:130-6.
128. Montenegro J. Cutaneous reaction in leishmaniasis. Arch Dermatol Syphillo 1926;13:187.
129. Marrano NM, Mata LJ, Durack DT. Cutaneous leishmaniasis in rural Costa Rica. Trnas R Soc Trop Med Hyg 1989; 83:340.
130. Reed SG, Carvalho EM, Sherbert CH, et al. In vitro responses to Leishmania antigens by lymphocytes from patients with leishmaniasis and Chagas' disease. J Clin Invest 1990;85:690-6.
131. Kalter DC. Laboratory tests for the diagnosis and evaluation of leishmaniasis. Dermatol Clin 1994;12:37-50.
132. Faber WR, Oskam L, Van Gool T, et al. Value of diagnostic techniques for cutaneous leishmaniasis. J Am Acad Dermatol 2003;49:70-4.
133. Ashford DA, Bozza M, Freire M, et al. Comparison of the polymerase chain reaction and serology for the detection of canine visceral leishmaniasis. Am J Trop Med Hyg 1995;53:251-5.
134. Desjeux P. Public health aspects and control. Clin Dermatol 1996;14:417-23.
135. Ashford RW. Cutaneous leishmaniasis: Strategies for prevention. Clin Dermatol 1999;17:327-32.
136. Alvar J. Control. En: Alvar J, editor. Las leishmaniasis: de la biología al control. 2.a ed. Salamanca: Laboratorios Intervet, 1997; p. 139-51.
137. Klaus NS, Frankenburg S, Ingber A. Epidemiology of cutaneous leishmaniasis. Clin Dermatol 1999;17:257-60.
138. Gratz NG, Steffen R, Cocksedge W. ¿Por qué desinsectar las aeronaves? Bull WHO 2000;78:995-1004.
139. Velez ID, Del Pilar Agudelo S, Arbelaez MP, et al. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. Trans R Soc Trop Med Hyg 2000;94:698-703.
140. Bahar K, Dowlati Y, Shidani B, et al. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol 1996;14:489-95.
141. Dowlati Y, Ehsasi S, Shidani B, et al. Stepwise safety trial of a killed Leishmania vaccine in Iran. Clin Dermatol 1996;14: 497-502.
142. Genaro O, Toledo VPCP, Costa CA, et al. Vaccine for prophylaxis and immunoterapy, Brazil. Clin Dermatol 1966;14:503-12.
143. Armijos RX, Weigel MM, Aviles H, et al. Field trial of a vaccine against New World cutaneous leishmaniasis in a at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow up. J Inf Dis 1998;177:1352-7.
144. Khalil EA, El Hassan AM, Zijlstra EE, et al. Autoclved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double blind, BCG-controlled trial in Sudan. Lancet 2000;356:1565-9.
145. Fonseca AL, De Vallochi AL, Furtado GC, et al. Immune response and protection in mice inoculated with Leishmania amazonensis clones expressing different degrees of virulence. Parasitol Res 1997;83:690-7.
146. Eisenberger CL, Jaffe CL. Vaccines against leishmanisis. En: Levine MM, Woodrow GC, Kaper JB, editors. Cobon GS, editors. New Generation Vaccines. 2.a ed. New York: Marcel Dekker, 1997; p. 1065-80.
147. Schilling S, Glaichenhaus N. T cells that react to the inmunodominanat Leishmania major LACK antigen prevent early dissemination of the parasite in susceptible BALB/c mice. Infect Immun 2001;69:1212-4.
148. Stager S, Smith DF, Kaye PM. Immunization with a recombinant stage-regulated protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 2000;165:7064-71.
149. Kamhwi S, Belkaid Y, Modi G, et al. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 2000;290:1351-4.
150. Ramsay AJ, Ramshaw IA, Ada GL. DNA immunization. Inmunol Cell Biol 1997;75:360-3.
151. El On J, Livshin R, Even-Paz Z. Topical Treatment of cutaneous leishmaniasis. J Invest Dermatol 1986;87:284-8.
152. El On J, Halevy S, Grunwald M, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double blind control study. J Am Acad Dermatol 1992;27:27-31.
153. Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Invest Drugs 2000;3:538-44.
154. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the inmunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999; 179:1485-94.
155. Aresis valo I, Ward B, Miller R, et al. Succesful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an inmunomodulator Clin Infect Dis 2001;33:1847-51.
156. Vilanova X. Las formas degenerativas de la Leishmania trópica en el curso de los tratamientos antimoniales Actas Dermo-Sif 1942;33:521-3.
157. Sáenz S, et al. Leishmaniasis tratada con Imiquimod. Actas Dermosifiliogr 2003;94(Supl 1):61-2.
158. Romaguera Llach C. Resultado terapéutico de un caso de leishmaniosis cutánea tratada intralesionalmente con una solución concentrada de hexonato de antimonio. Actas Dermo-Sif 1943;35:50-1.
159. Grau Barberá L. Tratamiento de la leishmaniosis cutánea con el soluesubosán a alta concentración. Actas Dermo-Sif 1943;34:287-91.
160. Mercadal Peyrí J. Sobre una nueva técnica en el tratamiento de la leishmaniosis cutánea. Actas Dermo-Sif 1944;35:381-8.
161. Grau Barberá L. Nota terapéutica sobre el tratamiento de la leishmaniosis cutánea con el hexonato de antimonio en solución concentrada y en aplicación intralesional. Actas Dermo-Sif 1943;34:302-8.
162. Cantó Ibáñez F. Leishmaniosis cutánea y soluestibosán. Actas Dermo-Sif 1945;36:774-7.
163. Ruiz-Villaverde R, Blasco Melguizo J, Linares Solano J, et al. Leishmaniasis cutánea crónica: respuesta a n-metil glucamina intralesional, tras fracaso con paromomicina tópica. Actas Dermosifiliogr 2002;93:263-6.
164. Kellum R. Treatment of cutaneous leishmaniasis with an intralesional antimonial drug (pentostam). J Am Acad Dermatol 1986;15:620-2.
165. Moskowitz P, Kurban AK. Treatment of cutaneous leishmaniasis: Retrospectives and advances for the 21st century. Clin Dermatol 1999;17:305-15.
166. Alcalde M, Delgado V, Gutiérrez MT, et al. Leishmaniosis cutáneas: alternativas terapéuticas al glucantime. Actas Dermo-Sif 1989;80:259-66.
167. Quiles J, Sánchez Pedreño J, Ortuño G, et al. Leishmaniasis cutánea palmar. Actas Dermo-Sif 1984;75:63-5.
168. Aparicio Fernández S, Moreno Presmanes M, Feliciano Divasson L, et al. Leishmaniasis cutánea extensa. Actas Dermosifiliogr 2000;91:29-38.
169. Neva F, Petersen E, Corsey R, et al. Observations on local heat treatment for cutaneous leishmaniasis. Am J Trop Med Hyg 1984;33:800-4.
170. Junaid A. Treatment of cutaneous leishmaniasis with infrared heat. Int J Dermatol 1986;25:470-2.
171. Aram H, Leibovici V. Ultrasound-induced hyperthermia in the treatment of cutaneous leishmaniasis. Cutis 1987;40: 350-3.
172. Sharkie K, Al-Hamamy H, El-Yassin D. Treatment of cutaneous leishmaniasis by direct current electrotherapy: The Baghdadin device. J Dermatol 1998;25:234-7.
173. Chen M, Christensen SB, Theander TG, Kharazuri A. Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsteres infected with Leishmania donovani. Antimicrob Agents Chemother 1994;38: 1339-44.
174. Koff AB, Rosen T. Treatment of cutaneous leishmaniasis. J Am Acad Dermatol 1994;31:693-708.
175. Dogra J. A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis. Trans Soc R Trop Med Hyg 1991;85:212-3.
176. Osorio L, Palacios R, Chica M, et al. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet 1998;351:498-9.
177. Singh S, Sudndar S, Singh V. Leishmaniasis: Recent advances in treatment. J Am Acad Dermatol 1997;37: 512-3.
178. Waechter A, Ferreira M, Fournet A, et al. Experimental treatment of cutaneous leishmaniasis with argentilactone isolated from Annone haematantha. Planta Med 1997;63: 433-5.
179. Chan C, Yin H, Garforth J, et al. Phenotiazine inhibitors of trypanothione reductase as potencial antitrypanosomal and antileishmanial drugs. J Med Chem 1998;41:148-56.
180. Zerehsaz F, Salmanpour R, Hanjani F, et al. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. Systemic meglumine antimoniate for the treatmen of cutaneous leishmaniasis in Iran. Int J Dermatol 1999;38:610-2.
181. Ghazanfari T, Hassan ZM, Ebtekar M, et al. Garlic induces a shift in cytokine pattern in Leishmania mojor-infected BALB/c mice. Scand J Inmunol 2000;52:491-5.
182. García Almagro D. Leishmaniasis cutánea. En: España Alonso A, editor. Fisiopatología de las enfermedades cutineas IV. Madrid: Aula Médica, 2004.